SK279615B6 - Alkaloidy z mappia foetida, spôsob ich výroby, ich - Google Patents
Alkaloidy z mappia foetida, spôsob ich výroby, ich Download PDFInfo
- Publication number
- SK279615B6 SK279615B6 SK834-94A SK83494A SK279615B6 SK 279615 B6 SK279615 B6 SK 279615B6 SK 83494 A SK83494 A SK 83494A SK 279615 B6 SK279615 B6 SK 279615B6
- Authority
- SK
- Slovakia
- Prior art keywords
- alkaloids
- water
- foetidine
- methanol
- preparation
- Prior art date
Links
- 229930013930 alkaloid Natural products 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims description 5
- 238000000034 method Methods 0.000 title claims 4
- 239000008194 pharmaceutical composition Substances 0.000 title claims 3
- 241000261227 Mappia foetida Species 0.000 title abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 3
- 230000000259 anti-tumor effect Effects 0.000 claims abstract 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- -1 aliphatic alcohols Chemical class 0.000 claims description 5
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 239000008346 aqueous phase Substances 0.000 claims description 2
- 239000002021 butanolic extract Substances 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 238000002953 preparative HPLC Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000006286 aqueous extract Substances 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract description 10
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 abstract description 9
- 229940127093 camptothecin Drugs 0.000 abstract description 9
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 abstract description 9
- 238000001212 derivatisation Methods 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- XVMZDZFTCKLZTF-NRFANRHFSA-N 9-methoxycamptothecin Chemical compound C1=CC(OC)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 XVMZDZFTCKLZTF-NRFANRHFSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XVMZDZFTCKLZTF-UHFFFAOYSA-N 9-methoxycamtothecin Natural products C1=CC(OC)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 XVMZDZFTCKLZTF-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002034 butanolic fraction Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KLFJSYOEEYWQMR-NRFANRHFSA-N 10-methoxycamptothecin Chemical compound C1=C(OC)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 KLFJSYOEEYWQMR-NRFANRHFSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 241000209018 Nyssaceae Species 0.000 description 1
- 101001077374 Oryza sativa subsp. japonica UMP-CMP kinase 3 Proteins 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000013098 chemical test method Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical group NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07G—COMPOUNDS OF UNKNOWN CONSTITUTION
- C07G5/00—Alkaloids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI941112A IT1269862B (it) | 1994-05-30 | 1994-05-30 | Alcaloidi da mappia foetida, loro uso e formulazioni che li contengono |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK83494A3 SK83494A3 (en) | 1995-12-06 |
| SK279615B6 true SK279615B6 (sk) | 1999-01-11 |
Family
ID=11369016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK834-94A SK279615B6 (sk) | 1994-05-30 | 1994-07-12 | Alkaloidy z mappia foetida, spôsob ich výroby, ich |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5525609A (cs) |
| EP (1) | EP0685481B1 (cs) |
| JP (1) | JP3615240B2 (cs) |
| KR (1) | KR0149723B1 (cs) |
| CN (1) | CN1052233C (cs) |
| AT (1) | ATE159527T1 (cs) |
| CA (1) | CA2127763C (cs) |
| CZ (1) | CZ290320B6 (cs) |
| DE (2) | DE69406430T2 (cs) |
| DK (1) | DK0685481T3 (cs) |
| ES (1) | ES2081783T3 (cs) |
| FI (1) | FI106202B (cs) |
| GR (2) | GR960300006T1 (cs) |
| HU (1) | HU216844B (cs) |
| IT (1) | IT1269862B (cs) |
| NO (1) | NO179640C (cs) |
| PL (1) | PL177042B1 (cs) |
| RU (1) | RU2123005C1 (cs) |
| SK (1) | SK279615B6 (cs) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5527913A (en) * | 1993-02-25 | 1996-06-18 | The Stehlin Foundation For Cancer Research | Methods for purifying camptothecin compounds |
| AU3684395A (en) * | 1994-10-06 | 1996-05-02 | Leon T. Atlas | Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases |
| IT1283635B1 (it) * | 1996-05-10 | 1998-04-23 | Indena Spa | Composti a scheletro camptotecinico isolati da mappia foetida e loro uso come sintoni per farmaci o come principi attivi |
| FR2792937B1 (fr) | 1999-04-27 | 2001-08-10 | Cemaf | NOUVEAUX DERIVES DE PYRROLO-(3,4-b) QUINOLEINE, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION A TITRE DE MEDICAMENT |
| AUPQ987400A0 (en) * | 2000-09-04 | 2000-09-28 | Food Ingredients Technologies Intangibles (Bermuda) Limited | Process for selectively extracting bioactive components |
| WO2003103610A2 (en) * | 2002-03-01 | 2003-12-18 | University Of Pittsburgh | Mappicine analogs, methods of inhibiting retroviral reverse transcriptase and methods of treating retroviruses |
| US6893668B2 (en) * | 2003-03-31 | 2005-05-17 | Council Of Scientific And Industrial Research | Process for isolation of anticancer agent camptothecin from Nothapodytes foetida |
| US20060135546A1 (en) * | 2004-12-16 | 2006-06-22 | Jagadevappa Basavaraja | Methods for the purification of 20(S)- camptothecin |
| CN103181272A (zh) * | 2011-12-28 | 2013-07-03 | 广东神农衍生物科技有限公司 | 一种药用原材料臭马比木的人工种植方法 |
| CN104619322B (zh) * | 2013-07-24 | 2016-10-19 | 张苑金 | 抗癌药物组合物及其制备方法和用途 |
| CN105053041A (zh) * | 2015-08-11 | 2015-11-18 | 长沙秋点兵信息科技有限公司 | 一种用于农作物的杀虫剂 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1332413C (en) * | 1987-06-25 | 1994-10-11 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
| JPS6461482A (en) * | 1987-08-31 | 1989-03-08 | Yakult Honsha Kk | Dehydrocamptothecin and production thereof |
| US5004746A (en) * | 1987-09-29 | 1991-04-02 | Merrell Dow Pharmaceuticals Inc. | Anti-retroviral castanospermine esters |
| JP2795460B2 (ja) * | 1988-06-20 | 1998-09-10 | 協和醗酵工業株式会社 | ピラゾロアクリドン誘導体 |
| IL94600A0 (en) * | 1989-06-06 | 1991-04-15 | Rhone Poulenc Sante | Pyridobenzoindole compounds,their preparation and compositions containing them |
| DE69209969T2 (de) * | 1991-10-29 | 1996-09-12 | Glaxo Wellcome Inc | Wasserlösliche Camptothecinderivate |
| EP0556585A3 (en) * | 1992-01-24 | 1993-09-01 | Takeda Chemical Industries, Ltd. | Condensed camptothecin derivatives their production and use as antitumor agents |
| IT1254517B (it) * | 1992-03-06 | 1995-09-25 | Indena Spa | 14-beta idrossi-10-deacetil-baccatina iii, suoi derivati, loro prepazione ed impiego terapeutico |
| AP9300587A0 (en) * | 1992-11-12 | 1995-05-05 | Glaxo Inc | Water soluble camptothecin derivatives. |
| US5352789A (en) * | 1993-02-25 | 1994-10-04 | The Stehlin Foundation For Cancer Research | Methods for purifying camptothecin compounds |
-
1994
- 1994-05-30 IT ITMI941112A patent/IT1269862B/it active IP Right Grant
- 1994-07-11 US US08/273,510 patent/US5525609A/en not_active Expired - Fee Related
- 1994-07-11 FI FI943294A patent/FI106202B/fi not_active IP Right Cessation
- 1994-07-11 CA CA002127763A patent/CA2127763C/en not_active Expired - Fee Related
- 1994-07-12 SK SK834-94A patent/SK279615B6/sk unknown
- 1994-07-13 EP EP94110864A patent/EP0685481B1/en not_active Expired - Lifetime
- 1994-07-13 HU HU9402089A patent/HU216844B/hu not_active IP Right Cessation
- 1994-07-13 NO NO942633A patent/NO179640C/no unknown
- 1994-07-13 RU RU94026100A patent/RU2123005C1/ru not_active IP Right Cessation
- 1994-07-13 DE DE69406430T patent/DE69406430T2/de not_active Expired - Fee Related
- 1994-07-13 DK DK94110864.9T patent/DK0685481T3/da active
- 1994-07-13 DE DE0685481T patent/DE685481T1/de active Pending
- 1994-07-13 AT AT94110864T patent/ATE159527T1/de not_active IP Right Cessation
- 1994-07-13 ES ES94110864T patent/ES2081783T3/es not_active Expired - Lifetime
- 1994-07-14 KR KR1019940016949A patent/KR0149723B1/ko not_active Expired - Fee Related
- 1994-07-15 CZ CZ19941718A patent/CZ290320B6/cs not_active IP Right Cessation
- 1994-07-25 JP JP17254294A patent/JP3615240B2/ja not_active Expired - Fee Related
- 1994-07-30 CN CN94114908A patent/CN1052233C/zh not_active Expired - Fee Related
- 1994-08-05 PL PL94304577A patent/PL177042B1/pl not_active IP Right Cessation
-
1996
- 1996-02-29 GR GR960300006T patent/GR960300006T1/el unknown
-
1997
- 1997-10-23 GR GR970402650T patent/GR3025120T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8299125B2 (en) | Water-soluble triterpenephenol compounds having antitumor activity and the preparation thereof | |
| SK279615B6 (sk) | Alkaloidy z mappia foetida, spôsob ich výroby, ich | |
| US7138428B2 (en) | Compounds isolated from gamboge resin having activity in inhibiting the growth of tumor/cancer cells and pharmaceutical compositions comprising the same | |
| KR0169536B1 (ko) | 신규한 인삼 사포닌, 그의 제조방법 및 이를 유효성분으로 하는 항종양제 | |
| KR980008225A (ko) | 데커시놀 안젤레이트를 유효성분으로 하는 항암제 | |
| CN103396470B (zh) | Withanolides型化合物及其抗肿瘤的用途 | |
| CN114409670A (zh) | 具有抗肿瘤活性苦木素类化合物及其制备方法与应用 | |
| WO2018153310A1 (zh) | 一种环烯醚萜类化合物及其制备方法和应用 | |
| CN107674054B (zh) | 一类新骨架杂萜化合物，其制备方法、药物组合物和抗肿瘤应用 | |
| Chanal et al. | Absorption and elimination of (14C) hesperidin methylchalcone in the rat | |
| HK1003833B (en) | Alkaloids from mappia foetida, the use thereof and formulations containing them | |
| CN118978484B (zh) | 高乌甲素及其制备方法、药物组合物和在抗抑郁药物中的应用 | |
| CN117586214B (zh) | 乌药烷型倍半萜二聚体及其制备方法和用途 | |
| CN113185528B (zh) | 选择性抗破骨细胞生物碱14-hydroxygelsenicine的药物应用 | |
| CN107522764B (zh) | 一种抗抑郁化合物 | |
| CN114539217B (zh) | 一种二聚异喹啉生物碱化合物及其制备和用途 | |
| CN100410271C (zh) | 一种具有抗肿瘤活性的化合物及其制备方法 | |
| CN115160399A (zh) | 一种皂皮酸类化合物及其制备方法和医用用途 | |
| CN115677471A (zh) | 玫瑰烷型二萜类化合物及制备、药物组合物和抗肿瘤应用 | |
| CN120329254A (zh) | 一种生物碱类化合物及其制备方法和应用 | |
| CN103159711B (zh) | 17-氢-9-去氢穿心莲内酯-3,19-二硫酸酯钠(或钾)、17-氢-9-去氢穿心莲内酯-19-硫酸酯钠(或钾)组合物的一次制备方法及其制备药物用途 | |
| JPH01290627A (ja) | 抗腫瘍剤 | |
| HK1084102A1 (en) | Compounds isolated from gamboge resin having activity in inhibiting the growth of tumor/cancer cells and pharmaceutical compositions comprising the same | |
| JPH0148888B2 (cs) | ||
| HK1084102B (en) | Compounds isolated from gamboge resin having activity in inhibiting the growth of tumor/cancer cells and pharmaceutical compositions comprising the same |